Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28639283 | 0.87 | ATM (0.75) | ATMKMT2AKDM4EALDH1A1GAA | |
| SCHEMBL249578 | 0.81 | NR4A1 (0.52) | CXCR5KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL29392762 | 0.79 | CNR1 (0.47) | KMT2ACXCR5KDM4EALDH1A1GAA | |
| SCHEMBL401068 | 0.79 | CNR1 (0.47) | KMT2ACXCR5KDM4EALDH1A1GAA | |
| SCHEMBL15237521 | 0.79 | CXCR5 (0.40) | ATMKMT2ACXCR5KDM4EALDH1A1 | |
| SCHEMBL4031210 | 0.79 | ALDH1A1 (0.57) | ATMKMT2ACXCR5ALDH1A1MAPT | |
| SCHEMBL5750127 | 0.78 | ATM (0.64) | ATMKMT2AKDM4EALDH1A1GAA | |
| SCHEMBL4959193 | 0.78 | CXCR5 (0.45) | ATMKMT2ACXCR5ALDH1A1MAPT | |
| SCHEMBL18797613 | 0.78 | CXCR5 (0.49) | CXCR5ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL7113717 | 0.77 | CXCR5 (0.49) | ATMKMT2ACXCR5ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026778-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | TIUMBIO CO., LTD. (KR) | 2025-01-23 | — | — | US | disclosed |
| EP-4365181-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | TiumBio Co., Ltd. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | disclosed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | ATM 2583/4885KMT2A 1371/4885CXCR5 1393/4885 |
| US-20250026778-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | LGALS3, LGALS1, LGALS3BP | ATM 3348/4885KMT2A 4691/4885CXCR5 444/4885 |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | ATM 1305/4885KMT2A 823/4885CXCR5 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.